Global ST2 Biomarker Market Insights, Forecast to 2028

Cardiac biomarkers are the substances that are released into the bloodstream when the heart is stressed or damaged. Suppression of tumorigenicity 2 (ST2) is one such biomarker used to help in measurement of heart failure risk to assess the treatment options. The ST2 biomarker is a member of the interleukin-1 receptor family biomarker. It is a strong predictor and most promising biomarker for both chronic and acute heart failure.
Market Analysis and Insights: Global ST2 Biomarker Market
The global ST2 Biomarker market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, ELISA Based ST2 Biomarker accounting for % of the ST2 Biomarker global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China ST2 Biomarker market size is valued at US$ million in 2021, while the North America and Europe ST2 Biomarker are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe ST2 Biomarker landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global ST2 Biomarker market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global ST2 Biomarker market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global ST2 Biomarker market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global ST2 Biomarker market.
Global ST2 Biomarker Scope and Market Size
ST2 Biomarker market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global ST2 Biomarker market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
ELISA Based ST2 Biomarker
Immunochromatography Based ST2 Biomarker
Segment by Application
Hospitals
Diagnostic Centres
Ambulatory Surgical Centres
Others
By Company
Thermo Fisher Scientific
BD
Roche
Abbott
Siemens
Bio-Rad
BioMerieux
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA